Evidence map›Paper›PMID 32642447›Full record

ArticleToxicology reports2020

Early microRNA indicators of PPARα pathway activation in the liver.

Brian N Chorley, Gleta K Carswell, Gail Nelson, Virunya S Bhat, Charles E Wood

Open access · goldAbstract read
In one paragraph

Article in Toxicology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Brian N ChorleyOffice of Research and Development, U.S. EPA, Research Triangle Park, North Carolina, 27711, USA.
Gleta K CarswellOffice of Research and Development, U.S. EPA, Research Triangle Park, North Carolina, 27711, USA.
Gail NelsonOffice of Research and Development, U.S. EPA, Research Triangle Park, North Carolina, 27711, USA.
Virunya S BhatNSF International, Ann Arbor, Michigan, 48105, USA.
Charles E WoodOffice of Research and Development, U.S. EPA, Research Triangle Park, North Carolina, 27711, USA.
Environmental Protection Agency · USNational Sanitation Foundation International · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are short non-coding RNA species that play key roles in post-transcriptional regulation of gene expression. MiRNAs also serve as a promising source of early biomarkers for different environmental exposures and health effects, although there is limited information linking miRNA changes to specific target pathways. In this study, we measured liver miRNAs in male B6C3F1 mice exposed to a known chemical activator of the peroxisome proliferator-activated receptor alpha (PPARα) pathway, di(2-ethylhexyl) phthalate (DEHP), for 7 and 28 days at concentrations of 0, 750, 1500, 3000, or 6000 ppm in feed. At the highest dose tested, DEHP altered 61 miRNAs after 7 days and 171 miRNAs after 28 days of exposure, with 48 overlapping miRNAs between timepoints. Analysis of these 48 common miRNAs indicated enrichment in PPARα-related targets and other pathways related to liver injury and cancer. Four of the 10 miRNAs exhibiting a clear dose trend were linked to the PPARα pathway: mmu-miRs-125a-5p, -182-5p, -20a-5p, and -378a-3p. mmu-miRs-182-5p and -378a-3p were subsequently measured using digital drop PCR across a dose range for DEHP and two related phthalates with weaker PPARα activity, di

Indexed as

Acox1, acyl-Coenzyme A oxidase 1Adverse outcome pathway (AOP)AhR, aryl hydrocarbon receptorAIC, Akaike Information CriterionALT, alanine aminotransferaseAOP, adverse outcome pathwayAST, aspartate aminotransferaseBBP, n-butyl benzyl phthalateBenchmark dose (BMD)BiomarkersBMDA, apical-based benchmark doseBMD, benchmark doseBMDL, BMD lower confidence intervalBMDT, transcriptional-based benchmark doseBMR, benchmark responseBROD, benzyloxyresorufin O-debenzylationCAR, constitutive androstane receptorddPCR, droplet digital polymerase chain reactionDEGs, differentially expressed genesDEHP, di (2-thylhexyl) phthalateDEmiRs, differentially expressed miRNAsDNOP, di-n-octyl phthalateEPA, U.S. Environmental Protection AgencyEROD, ethoxyresorufin O-dealkylationGEO, Gene Expression OmnibusHCA, hepatocellular adenomaHCC, hepatocellular carcinomaHepatocellular carcinomaIPA, Ingenuity Pathway AnalysisLiver toxicityMicroRNAsmiRNAs, microRNAsMOA, mode of actionMode of action (MOA)mRNA, messenger RNAmtDNA, mitochondrialNrf2, nuclear receptor erythroid 2-like 2Peroxisome proliferator-activated receptor alpha (PPARα)PhthalatePOD, point-of-departurePPARα, peroxisome proliferator-activated receptor alphaPROD, pentoxyresorufin O-depentylationPXR, pregnane X receptorrRNA, ribosomal RNASDH, sorbitol dehydrogenasesmallRNA-seq, small RNA sequencingTMM, trimmed mean of M-valuestRNA, transfer RNA

Identifiers

PMID32642447
PMCPMC7334544
OpenAlexW3037806570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.